**Table of Contents**

**eMethods (page 2)** Functional forms of continuous variables and calculating VACS Index

**eFigure 1 (page 3)** Distribution of all 1244 Covid-19 cases in the VA as of March 30, 2020

**eTable 1 (page 4)** Code lists for baseline conditions

**eTable 2 (page 5)** Complete-case analysis of testing positive for Covid-19

**eTable 3 (page 6)** Complete-cases analysis of hospitalization and intensive care among Covid-19+

**eReferences (page 7)**

**eMethods**

*Functional forms of vital signs and laboratory results*

After assessing the distribution and crude shapes of associations, each vital sign and laboratory measure used in multivariable analyses were processed for analysis using the following steps. Body mass index (BMI) was treated as a linear variable and assessed per 5 kg/m2 increase, which broadly aligns with widely used categories. Pulse rate was treated as a linear variable and assessed per 5-beats per minute increase. Temperature was treated as a linear variable and assessed per 1°F increase.

We transformed systolic blood pressure, oxygen saturation, and all labs used in multivariable analyses to benefit clinical interpretation. Systolic blood pressure values above 140 mm Hg were truncated, and we assessed linear associations per 5 mm Hg decrease. Oxygen saturation values above 98% were truncated, and we assessed linear associations per 1% decrease. Albumin values above 4 g/dL were truncated, and we assessed linear associations per 1 g/dL decrease. eGFR values above 90 mL/min were truncated, and we assessed linear associations per 10 mL/min decrease. Hemoglobin values above 14 g/dL were truncated, and we assessed linear associations per 1 g/dL decrease. White blood cell counts below 4 K/µL and above 10 K/µL were truncated, and we assessed linear associations per 1 K/µL increase. Lymphocyte counts above 5 K/µL were truncated, and we assessed linear associations per 1 K/µL decrease. VACS Index score was treated as a linear variable and assessed per 5-point increase.

*Calculating VACS Index*

Full details on constructing the VACS Index in a Veteran population have been published previously.1 In brief, the VACS Index is a summary measure combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index. (Among people with HIV, we also consider HIV-1 viral load and CD4 count. These components were not used in this analysis.) Composite markers of liver and renal injury were calculated. FIB-4 is a validated indicator of liver fibrosis.2 Estimated glomerular filtration rate (eGFR) is a validated indicator of impaired renal function.3 Hepatitis C status was based on presence of ICD-10-CM codes (**eTable 1**).

Because clinicians tend to order laboratory tests that they are concerned to be abnormal, we assumed laboratory values as normal if it was the only missing value for calculating the VACS Index. We used continuous functional forms for each variable including quadratic, cubic, and natural log terms to account for U-shaped associations. Splines were used for eGFR. Using regression coefficients from the original validation work, we applied regression equations to each patient using their lab values and the model coefficients to create linear predictors for each patient, which were then scaled to create scores of approximately 0 to 100.

![A close up of a map

Description automatically generated]()

|  |  |  |  |
| --- | --- | --- | --- |
| eTable 1. Conditions based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes | | | |
|  |  |  | **ICD-10-CM codes** |
| **Comorbid conditions** | | |  |
|  | **Asthma** |  | J45.X |
|  | **Cancer** |  |  |
|  |  | Cancer | C00.X-C43.X, C45.X-C76.X, C80.X-C96.X, C7A.X |
|  |  | Metastatic cancer | C77.X-C79.X |
|  | **Chronic obstructive pulmonary disease** | | J41.X, J42.X, J43.X, J44.X |
|  | **Chronic kidney disease** | | I12.0X, I13.1X, N03.2X-N03.7X, N18.X, N19.X, N05.2X-N05.7X, N25.0X, Z49.0X - Z49.2X, Z94.0X, Z99.2X |
|  | **Diabetes mellitus** | | E08.X, E10.X, E11.X, E13.X |
|  | **Hypertension** | | I10.X-I13.X, I15.X, I16.X |
|  | **Liver disease** | |  |
|  |  | Hepatitis B virus | B16.X, B18.0X, B18.1X, B19.1X, Z22.51 |
|  |  | Hepatitis C virus | B17.10, B17.11, B18.2, B19.20, B19.21, Z22.52 |
|  |  | Hepatic decompensation | I85.01, K65.2, K70.31, K72.1X, K72.9X, K76.7, R18.8 |
|  |  | Other mild liver disease | B18.8X, B18.9X, K70.0X-K70.2X, K70.30, K70.9X, K71.3X-K71.5X, K71.7X, K73.X, K74.X, K76.0X, K76.2X-K76.4X, K76.8X, K76.9X, Z94.4 |
|  |  | Other severe liver disease | K76.6, I85.00, I85.9X, I86.4, I98.2X, K70.4X, K71.1X, K76.5X |
|  | **Vascular disease** | |  |
|  |  | Acute myocardial infarction | I21.X (not including I21.AX), I22.X |
|  |  | Cardiomyopathy | I42.X, I43.X |
|  |  | Coronary heart disease | I20.X, I24.X, I25.10, I25.110, I25.2, I25.3, I25.41, I25.42, I25.5, I25.700, I25.710, I25.720, I25.730, I25.750, I25.760, I25.790, I25.8X, I25.9 |
|  |  | Heart failure | I09.9, I11.0, I25.5, I13.0, I13.2, I50.X, P29.0 |
|  |  | Cerebrovascular accident | I60.X-I69.X, G45.X, G46.X, H34.0 |
|  |  | Peripheral vascular disease | I70.X, I71.X, I73.1-I73.9, I77.1, I79.0, I79.2, K55.1X, K55.8X, K55.9X, Z95.8X, Z95.9 |
| **Substance use** | |  |  |
|  | **Alcohol use disorder** | | F10.1X, F10.2X |

|  |  |  |  |
| --- | --- | --- | --- |
| **eTable 2.** Complete-case analysis estimating crude and adjusted associations with testing positive for Covid-19 as of March 30, 2020 | | | |
|  | **Positive Covid-19 test (n=585/3789)** | | |
|  | **Univariable OR (95% CI)** | **Multivariable OR (95% CI)** | **Conditional ORa (95% CI)** |
| **Model details** |  |  |  |
| Number complete cases | - | 2458 | 1366 |
| *C*-statistic | - | 0.820 | n/a |
|  |  |  |  |
| **Demographics** |  |  |  |
| Age, per 5-year increase | 1.04 (0.97-1.12) | 1.04 (0.93-1.15) | 1.04 (0.91-1.19) |
| Sex, male vs. female | 2.49 (1.67-3.73) | 3.51 (2.06-5.95) | 4.59 (2.37-8.89) |
| Race/ethnicity, black vs. other | 4.66 (3.88-5.60) | 5.68 (4.43-7.28) | 2.71 (1.91-3.86) |
| Residence type, urban vs. rural | 2.46 (1.84-3.28) | 1.65 (1.12-2.44) | 1.00 (0.56-1.78) |
|  |  |  |  |
| **Baseline comorbidity** |  |  |  |
| Chronic kidney disease, yes vs. no | 1.43 (1.14-1.80) | 1.02 (0.74-1.40) | 1.01 (0.68-1.50) |
| Chronic obstructive pulmonary disease, yes vs. no | 0.46 (0.37-0.59) | 0.69 (0.51-0.93) | 0.81 (0.55-1.19) |
| Diabetes mellitus, yes vs. no | 1.39 (1.16-1.66) | 0.96 (0.74-1.25) | 0.78 (0.56-1.08) |
| Hypertension, yes vs.no | 1.49 (1.23-1.81) | 1.27 (0.93-1.75) | 1.41 (0.95-2.11) |
|  |  |  |  |
| **Substance use** |  |  |  |
| Alcohol use disorder, yes vs. no | 0.51 (0.37-0.69) | 0.52 (0.35-0.78) | 0.48 (0.29-0.78) |
| Current smoking, yes vs. no | 0.43 (0.35-0.52) | 0.41 (0.31-0.53) | 0.41 (0.30-0.58) |
|  |  |  |  |
| **Medication history in year prior to test date** |  |  |  |
| Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, yes vs. no | 1.17 (0.98-1.39) | 1.05 (0.81-1.37) | 0.98 (0.70-1.36) |
| Nonsteroidal anti-inflammatory drug, yes vs. no | 1.15 (0.95-1.39) | 1.31 (1.01-1.69) | 1.18 (0.85-1.64) |
|  |  |  |  |
| **Vital signs** |  |  |  |
| Systolic blood pressure, <140 vs. ≥140 mm Hg | 1.22 (1.01-1.47) | 1.46 (1.14-1.86) | 1.47 (1.08-2.00) |
| Body mass index, per 5-unit increase | 1.15 (1.08-1.23) | 1.09 (0.99-1.19) | 1.12 (1.00-1.25) |
| Oxygen saturation, ≤93% vs >93% | 0.84 (0.64-1.09) | 0.98 (0.71-1.37) | 0.96 (0.60-1.54) |
| Pulse, per 5-beats per minute increase | 1.05 (1.02-1.08) | 1.03 (1.00-1.07) | 1.05 (1.00-1.10) |
| Temperature, per 1°F increase | 1.73 (1.61-1.85) | 1.62 (1.48-1.78) | 1.55 (1.38-1.74) |
| Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval | | | |
| aModeling stations with five or more Covid-19 cases and conditioning on station | | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **eTable 3.** Complete-case analysis estimating crude and adjusted associations with hospitalization and intensive care among Covid-19 cases as of March 30, 2020 | | | | | | | |
|  | **Hospitalization (n=297/585)** | | |  | **Intensive care (n=122/585)** | | |
|  | **Univariable OR (95% CI)** | **Multivariable OR (95% CI)** | **Multivariable OR (95% CI)** |  | **Univariable OR (95% CI)** | **Multivariable OR (95% CI)** | **Multivariable OR (95% CI)** |
| **Model details** |  |  |  |  |  |  |  |
| Number complete cases | - | 404 | 484 |  | - | 404 | 484 |
| *C*-statistic | - | 0.822 | 0.812 |  | - | 0.864 | 0.828 |
|  |  |  |  |  |  |  |  |
| **Demographics** |  |  |  |  |  |  |  |
| Age, per 5-year increase | 1.26 (1.10-1.44) | 0.97 (0.78-1.21) | 0.67 (0.53-0.85) |  | 1.55 (1.30-1.86) | 1.33 (1.01-1.74) | 1.03 (0.79-1.35) |
| Race/ethnicity, black vs. other | 1.30 (0.94-1.82) | 1.04 (0.60-1.78) | 1.08 (0.68-1.71) |  | 0.92 (0.61-1.38) | 0.94 (0.50-1.75) | 1.01 (0.59-1.71) |
|  |  |  |  |  |  |  |  |
| **Baseline comorbidity** |  |  |  |  |  |  |  |
| Chronic kidney disease, yes vs. no | 2.36 (1.53-3.66) | 0.97 (0.45-2.09) | 0.93 (0.50-1.74) |  | 1.73 (1.08-2.77) | 0.58 (0.25-1.33) | 0.80 (0.42-1.52) |
| Chronic obstructive pulmonary disease, yes vs. no | 2.31 (1.43-3.71) | 1.34 (0.64-2.85) | 0.98 (0.51-1.87) |  | 1.93 (1.17-3.18) | 1.21 (0.56-2.58) | 1.21 (0.63-2.35) |
| Diabetes mellitus, yes vs. no | 1.96 (1.41-2.73) | 1.62 (0.95-2.77) | 1.36 (0.86-2.15) |  | 2.20 (1.46-3.30) | 1.79 (0.94-3.39) | 1.45 (0.85-2.48) |
| Hypertension, yes vs.no | 2.25 (1.55-3.26) | 1.23 (0.64-2.37) | 1.62 (0.92-2.85) |  | 2.82 (1.63-4.88) | 1.65 (0.68-4.01) | 1.89 (0.88-4.05) |
| Vascular disease, yes vs. no | 2.92 (1.99-4.29) | 1.36 (0.75-2.46) | 1.51 (0.88-2.57) |  | 1.96 (1.29-2.99) | 0.75 (0.39-1.43) | 0.80 (0.45-1.42) |
|  |  |  |  |  |  |  |  |
| **Medication history in year prior to test date** |  |  |  |  |  |  |  |
| Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, yes vs. no | 1.63 (1.17-2.27) | 1.15 (0.66-1.99) | 1.15 (0.71-1.86) |  | 1.94 (1.30-2.90) | 1.44 (0.78-2.68) | 1.57 (0.92-2.70) |
| Nonsteroidal anti-inflammatory drug, yes vs. no | 0.78 (0.55-1.10) | 1.06 (0.62-1.80) | 1.01 (0.64-1.59) |  | 0.67 (0.43-1.04) | 0.97 (0.50-1.85) | 0.85 (0.48-1.50) |
|  |  |  |  |  |  |  |  |
| **Vital signs** |  |  |  |  |  |  |  |
| Systolic blood pressure, per 5 mm Hg decrease | 1.11 (1.04-1.18) | 1.12 (1.01-1.23) | 1.09 (1.00-1.18) |  | 1.05 (0.98-1.13) | 1.01 (0.91-1.11) | 1.00 (0.92-1.10) |
| Oxygen saturation, per 1% decrease | 1.15 (1.07-1.24) | 1.07 (0.95-1.19) | 1.14 (1.03-1.25) |  | 1.16 (1.09-1.24) | 1.05 (0.96-1.15) | 1.11 (1.03-1.19) |
| Pulse, per 5-beats per minute increase | 1.06 (1.01-1.12) | 1.03 (0.95-1.11) | 1.02 (0.95-1.10) |  | 1.13 (1.06-1.20) | 1.13 (1.04-1.23) | 1.12 (1.03-1.21) |
| Temperature, per 1°F increase | 1.20 (1.07-1.36) | 1.14 (0.96-1.36) | 1.24 (1.06-1.45) |  | 1.28 (1.12-1.47) | 1.33 (1.08-1.63) | 1.36 (1.14-1.61) |
|  |  |  |  |  |  |  |  |
| **Laboratory findings** |  |  |  |  |  |  |  |
| Albumin, per 1 g/dL decrease | 10.92 (5.88-20.25) | 2.70 (1.27-5.73) | - |  | 5.91 (3.45-10.12) | 3.99 (1.81-8.80) | - |
| eGFR, per 10 mL/min decrease | 1.29 (1.19-1.39) | 1.15 (1.00-1.31) | - |  | 1.31 (1.20-1.42) | 1.29 (1.12-1.48) | - |
| FIB-4 |  |  |  |  |  |  |  |
| <1.45 | ref | ref | - |  | ref | ref | - |
| 1.45-3.25 | 3.98 (2.53-6.25) | 2.11 (1.11-4.02) | - |  | 7.42 (3.13-17.62) | 4.59 (1.39-15.13) | - |
| >3.25 | 13.45 (7.28-24.84) | 5.52 (2.39-12.75) | - |  | 13.93 (5.66-34.29) | 6.88 (1.94-24.39) | - |
| Hemoglobin, per 1 g/L decrease | 1.51 (1.29-1.78) | 1.09 (0.85-1.40) | - |  | 1.28 (1.10-1.48) | 0.96 (0.75-1.21) | - |
| White blood cell count, per 1 K/µL increase | 1.06 (0.97-1.16) | 1.23 (1.05-1.44) | - |  | 1.23 (1.11-1.37) | 1.41 (1.18-1.68) | - |
| Lymphocyte count, per 1 K/µL decrease | 2.62 (1.95-3.52) | 2.30 (1.52-3.46) | - |  | 2.52 (1.70-3.74) | 2.42 (1.44-4.07) | - |
| VACS Index scorea, per 5-point increase | 1.47 (1.35-1.60) | - | 1.55 (1.36-1.77) |  | 1.45 (1.33-1.58) | - | 1.44 (1.27-1.64) |
| Abbreviations: Covid-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate, FIB-4, fibrosis 4 score; VACS, Veterans Aging Cohort Study | | | | | | | |
| aThe VACS Index score is a validated measure of physiologic injury combining age, aspartate and alanine transaminase, albumin, creatinine, hemoglobin, platelets, white blood cell count, hepatitis C status, and body mass index | | | | | | | |

**eReferences**

1. Tate JP, Sterne JAC, Justice AC, Veterans Aging Cohort S, the Antiretroviral Therapy Cohort C. Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. *AIDS.* 2019;33(5):903-912.

2. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology.* 2006;43(6):1317-1325.

3. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150(9):604-612.